產品名稱 |
Fowlpox virus |
商品貨號 |
B162864 |
Classification |
Poxviridae, Avipoxvirus |
Deposited As |
Fowlpox virus, Avipoxvirus |
Agent |
Fowlpox virus |
Strain |
FPV/MDVgBh [Recombinant vaccine for Marek's disease] |
Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Product Format |
frozen |
Storage Conditions |
-70°C or colder |
Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
Images |
|
Comments |
Recombinant vaccine for Marek’s disease in chicken containing glycoprotein B homologue. The insert has the LacZ marker, producing blue plaques in the presence of Blu-o-Gal in the agar. |
Effect on Host |
CPE, rounding and sloughing |
Recommended Host |
SL-29 (ATCC® CRL-1590™) |
Growth Conditions |
Temperature: 37°C
Recommendations for Infection: For best results, infection should be performed on an 80-90% confluent, 18-48 hour old cellular monolayer. Prepare dilution of virus in minimum amount of volume (e.g. 1 mL per 25 cm2). Wash monolayer with PBS or serum free medium prior to inoculation. Adsorb virus dilution for 1-2 hours at 37°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
Incubation: 1-4 days at 37°C in a humidified 5% CO2 atmosphere, until CPE is progressed through 80% of the monolayer. |
Name of Depositor |
K. Nazerian, USDA/ARS |
U.S. Patent |
|
U.S. Patent Number |
|
References |
Nazerian K, et al. Recombinant fowlpox vaccine for protection against Marek's disease. US Patent 5,369,025 dated Nov 29 1994
|